Loading
A leading authority on inherited cancer risk and how BRCA carriers should be treated and screened.
Judy E. Garber is Chief of the Division of Cancer Genetics and Prevention and holds the Susan F. Smith Chair at Dana-Farber Brigham Cancer Center. She is a leading authority on inherited cancer risk and on how BRCA carriers should be treated and screened, having contributed to the TBCRC neoadjuvant cisplatin trials in BRCA-associated breast cancer and to the OlympiA trial. Her selected paper reports adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. She directs cancer genetics and prevention at Dana-Farber, spanning germline testing, chemoprevention and risk-reducing surgery.
| Title | Journal | Year |
|---|---|---|
| Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer | New England Journal of Medicine | 2021 |
Answers the two questions that hung over adjuvant olaparib, durability and late leukaemia, in its favour; the remaining question is whether carriers who also received pembrolizumab or capecitabine, whom the trial did not study, get the same benefit.
The survival result that moved adjuvant olaparib from a disease-free survival approval to an undisputed standard, and the reason germline testing at diagnosis of triple-negative breast cancer is now a treatment decision rather than a family history exercise.
Everyone with HER2-negative early breast cancer that meets high-risk criteria should be offered germline BRCA testing, because a positive result now changes treatment: a year of olaparib after chemotherapy reduces relapse and death. It does not apply to low-risk tumours, HER2-positive disease, or somatic-only BRCA mutations.
Shares Angelina Jolie, OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing.
Shares Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial, Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer, OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer, OlympiA.
Shares OlympiA, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Germline (hereditary) testing.
Shares Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer, OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer, OlympiA, BRCA1 / BRCA2 (HRD).
Shares Mary-Claire King, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Germline (hereditary) testing.
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Germline (hereditary) testing, Ovarian cancer.
Shares Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial, OlympiA, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem.
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Germline (hereditary) testing, Triple-negative breast cancer (TNBC).